SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): September 15, 2000
------------------
DIACRIN, INC.
------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 000-20139 22-3016912
---------------------------- ------------------------ -------------------
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
Building 96 13th Street, Charlestown Navy Yard, Charlestown, MA 02129
--------------------------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
(617) 242-9100
--------------------------------------------------
Registrant's Telephone Number, Including Area Code
Not Applicable
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
- 1 -
<PAGE>
Item 5. OTHER EVENTS
On September 14, 2000, Diacrin, Inc. ("Diacrin"), along with its joint
venture partner Genzyme Corporation, issued a press release. A copy of the press
release is attached hereto as an exhibit and incorporated herein by reference.
- 2 -
<PAGE>
SIGNATURES
Pusuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
DIACRIN, INC.
(Registrant)
Date: September 15, 2000 By: /s/ Thomas H. Fraser
-----------------------
President and CEO
- 3 -
<PAGE>
INDEX TO EXHIBITS
Exhibit
Number Description
------- -----------
99.1 Press Release issued September 14, 2000
- 4 -
